Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma
Gespeichert in:
| Veröffentlicht in: | Blood 2022-11, Vol.140 (Supplement 1), p.6531-6533 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6533 |
|---|---|
| container_issue | Supplement 1 |
| container_start_page | 6531 |
| container_title | Blood |
| container_volume | 140 |
| creator | Merryman, Reid W Redd, Robert A. Freedman, Arnold S. Ahn, Inhye E. Brown, Jennifer R. Crombie, Jennifer L. Davids, Matthew S. Fisher, David C. Jacobsen, Eric D Kim, Austin I. LaCasce, Ann S. Ng, Samuel Odejide, Oreofe O. Parry, Erin Michelle Isufi, Iris Kline, Justin Cohen, Jonathon B. Mehta-Shah, Neha Bartlett, Nancy L. Mei, Matthew Armand, Philippe Jacobson, Caron A. |
| description | |
| doi_str_mv | 10.1182/blood-2022-159823 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_159823</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122044603</els_id><sourcerecordid>S0006497122044603</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1373-1909d5ca2f6bf1cb0123aa7a9720dcc0647069bdfe44bba3f1dc75fa80fb1e533</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EEqXwAez8A4GxnadYVYFCpUqgCtaWn9SQxJGdQvv3pIQ1q1ncOaM7B6FrAjeElPRWNt7rhAKlCcmqkrITNCMZLRMACqdoBgB5klYFOUcXMX4AkJTRbIb29zvR4FXb7jqD661Rn7133YAX76YbInYdrn0rXScG5zv87YYt3rhht3etkNj6gF_G5Hd1ykwj-mg0HpONsUGowYcDXvqmcWrXiIDXh7bf-lZcojMrmmiu_uYcvS0fXuunZP38uKoX60QRVrCEVFDpTAlqc2mJkkAoE6IQVUFBKwV5WkBeSW1NmkopmCVaFZkVJVhJTMbYHJHprgo-xmAs78NYPhw4AX5Ux3_V8aM6PqkbmbuJMWOxL2cCj2p8UhntglED1979Q_8AsOZ5uw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Merryman, Reid W ; Redd, Robert A. ; Freedman, Arnold S. ; Ahn, Inhye E. ; Brown, Jennifer R. ; Crombie, Jennifer L. ; Davids, Matthew S. ; Fisher, David C. ; Jacobsen, Eric D ; Kim, Austin I. ; LaCasce, Ann S. ; Ng, Samuel ; Odejide, Oreofe O. ; Parry, Erin Michelle ; Isufi, Iris ; Kline, Justin ; Cohen, Jonathon B. ; Mehta-Shah, Neha ; Bartlett, Nancy L. ; Mei, Matthew ; Armand, Philippe ; Jacobson, Caron A.</creator><creatorcontrib>Merryman, Reid W ; Redd, Robert A. ; Freedman, Arnold S. ; Ahn, Inhye E. ; Brown, Jennifer R. ; Crombie, Jennifer L. ; Davids, Matthew S. ; Fisher, David C. ; Jacobsen, Eric D ; Kim, Austin I. ; LaCasce, Ann S. ; Ng, Samuel ; Odejide, Oreofe O. ; Parry, Erin Michelle ; Isufi, Iris ; Kline, Justin ; Cohen, Jonathon B. ; Mehta-Shah, Neha ; Bartlett, Nancy L. ; Mei, Matthew ; Armand, Philippe ; Jacobson, Caron A.</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-159823</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.6531-6533</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Merryman, Reid W</creatorcontrib><creatorcontrib>Redd, Robert A.</creatorcontrib><creatorcontrib>Freedman, Arnold S.</creatorcontrib><creatorcontrib>Ahn, Inhye E.</creatorcontrib><creatorcontrib>Brown, Jennifer R.</creatorcontrib><creatorcontrib>Crombie, Jennifer L.</creatorcontrib><creatorcontrib>Davids, Matthew S.</creatorcontrib><creatorcontrib>Fisher, David C.</creatorcontrib><creatorcontrib>Jacobsen, Eric D</creatorcontrib><creatorcontrib>Kim, Austin I.</creatorcontrib><creatorcontrib>LaCasce, Ann S.</creatorcontrib><creatorcontrib>Ng, Samuel</creatorcontrib><creatorcontrib>Odejide, Oreofe O.</creatorcontrib><creatorcontrib>Parry, Erin Michelle</creatorcontrib><creatorcontrib>Isufi, Iris</creatorcontrib><creatorcontrib>Kline, Justin</creatorcontrib><creatorcontrib>Cohen, Jonathon B.</creatorcontrib><creatorcontrib>Mehta-Shah, Neha</creatorcontrib><creatorcontrib>Bartlett, Nancy L.</creatorcontrib><creatorcontrib>Mei, Matthew</creatorcontrib><creatorcontrib>Armand, Philippe</creatorcontrib><creatorcontrib>Jacobson, Caron A.</creatorcontrib><title>Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAQRS0EEqXwAez8A4GxnadYVYFCpUqgCtaWn9SQxJGdQvv3pIQ1q1ncOaM7B6FrAjeElPRWNt7rhAKlCcmqkrITNCMZLRMACqdoBgB5klYFOUcXMX4AkJTRbIb29zvR4FXb7jqD661Rn7133YAX76YbInYdrn0rXScG5zv87YYt3rhht3etkNj6gF_G5Hd1ykwj-mg0HpONsUGowYcDXvqmcWrXiIDXh7bf-lZcojMrmmiu_uYcvS0fXuunZP38uKoX60QRVrCEVFDpTAlqc2mJkkAoE6IQVUFBKwV5WkBeSW1NmkopmCVaFZkVJVhJTMbYHJHprgo-xmAs78NYPhw4AX5Ux3_V8aM6PqkbmbuJMWOxL2cCj2p8UhntglED1979Q_8AsOZ5uw</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Merryman, Reid W</creator><creator>Redd, Robert A.</creator><creator>Freedman, Arnold S.</creator><creator>Ahn, Inhye E.</creator><creator>Brown, Jennifer R.</creator><creator>Crombie, Jennifer L.</creator><creator>Davids, Matthew S.</creator><creator>Fisher, David C.</creator><creator>Jacobsen, Eric D</creator><creator>Kim, Austin I.</creator><creator>LaCasce, Ann S.</creator><creator>Ng, Samuel</creator><creator>Odejide, Oreofe O.</creator><creator>Parry, Erin Michelle</creator><creator>Isufi, Iris</creator><creator>Kline, Justin</creator><creator>Cohen, Jonathon B.</creator><creator>Mehta-Shah, Neha</creator><creator>Bartlett, Nancy L.</creator><creator>Mei, Matthew</creator><creator>Armand, Philippe</creator><creator>Jacobson, Caron A.</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma</title><author>Merryman, Reid W ; Redd, Robert A. ; Freedman, Arnold S. ; Ahn, Inhye E. ; Brown, Jennifer R. ; Crombie, Jennifer L. ; Davids, Matthew S. ; Fisher, David C. ; Jacobsen, Eric D ; Kim, Austin I. ; LaCasce, Ann S. ; Ng, Samuel ; Odejide, Oreofe O. ; Parry, Erin Michelle ; Isufi, Iris ; Kline, Justin ; Cohen, Jonathon B. ; Mehta-Shah, Neha ; Bartlett, Nancy L. ; Mei, Matthew ; Armand, Philippe ; Jacobson, Caron A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1373-1909d5ca2f6bf1cb0123aa7a9720dcc0647069bdfe44bba3f1dc75fa80fb1e533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Merryman, Reid W</creatorcontrib><creatorcontrib>Redd, Robert A.</creatorcontrib><creatorcontrib>Freedman, Arnold S.</creatorcontrib><creatorcontrib>Ahn, Inhye E.</creatorcontrib><creatorcontrib>Brown, Jennifer R.</creatorcontrib><creatorcontrib>Crombie, Jennifer L.</creatorcontrib><creatorcontrib>Davids, Matthew S.</creatorcontrib><creatorcontrib>Fisher, David C.</creatorcontrib><creatorcontrib>Jacobsen, Eric D</creatorcontrib><creatorcontrib>Kim, Austin I.</creatorcontrib><creatorcontrib>LaCasce, Ann S.</creatorcontrib><creatorcontrib>Ng, Samuel</creatorcontrib><creatorcontrib>Odejide, Oreofe O.</creatorcontrib><creatorcontrib>Parry, Erin Michelle</creatorcontrib><creatorcontrib>Isufi, Iris</creatorcontrib><creatorcontrib>Kline, Justin</creatorcontrib><creatorcontrib>Cohen, Jonathon B.</creatorcontrib><creatorcontrib>Mehta-Shah, Neha</creatorcontrib><creatorcontrib>Bartlett, Nancy L.</creatorcontrib><creatorcontrib>Mei, Matthew</creatorcontrib><creatorcontrib>Armand, Philippe</creatorcontrib><creatorcontrib>Jacobson, Caron A.</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Merryman, Reid W</au><au>Redd, Robert A.</au><au>Freedman, Arnold S.</au><au>Ahn, Inhye E.</au><au>Brown, Jennifer R.</au><au>Crombie, Jennifer L.</au><au>Davids, Matthew S.</au><au>Fisher, David C.</au><au>Jacobsen, Eric D</au><au>Kim, Austin I.</au><au>LaCasce, Ann S.</au><au>Ng, Samuel</au><au>Odejide, Oreofe O.</au><au>Parry, Erin Michelle</au><au>Isufi, Iris</au><au>Kline, Justin</au><au>Cohen, Jonathon B.</au><au>Mehta-Shah, Neha</au><au>Bartlett, Nancy L.</au><au>Mei, Matthew</au><au>Armand, Philippe</au><au>Jacobson, Caron A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>6531</spage><epage>6533</epage><pages>6531-6533</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-159823</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2022-11, Vol.140 (Supplement 1), p.6531-6533 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_crossref_primary_10_1182_blood_2022_159823 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T10%3A53%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dual%20Immune%20Checkpoint%20Agents%20in%20Combination%20with%20Rituximab%20for%20Patients%20with%20Relapsed%20or%20Refractory%20Follicular%20Lymphoma&rft.jtitle=Blood&rft.au=Merryman,%20Reid%20W&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=6531&rft.epage=6533&rft.pages=6531-6533&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-159823&rft_dat=%3Celsevier_cross%3ES0006497122044603%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122044603&rfr_iscdi=true |